Settled
Do SGLT2 inhibitors improve body weight & composition versus placebo?
Mostly studied in obesity & overweight. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Very likely. So far, established.
NoUnsureYes
- Belief
- 0.98 (range 0.86–1.00)
- Trials for
- 50
- Trials against
- 1
- Inconclusive
- 9
Already under way
- Treating the Metabolic Syndrome With a Sodium-glucose Cotransporter-2 Inhibitor: a Randomised Controlled TrialNCT07065357 · enrolling by invitation · started 2025
- Role of Empagliflozin in Metabolic Changes Associated With Antiretroviral Therapy in Human Immunodeficiency VirusNCT07336797 · recruiting · started 2025
- The Effect of Sodium Glucose Co-transporter 2 Inhibitor (dapagliflozin) on Weight Loss in Non-diabetic Adults with Obesity: Triple-blinded, Randomized,…NCT06000462 · active not recruiting · started 2024
- Effectiveness of Pharmacologic, Surgical, and Dietetic Weight Loss Methods on Lifespan in Patients With Metabolic Syndrome: a Comparative Clinical TrialNCT06410352 · recruiting · started 2024
- Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in HispanicsNCT06446531 · recruiting · started 2024
The evidence so far
- Registered trials
- 310
- With posted results
- 116
- Published papers
- 16
Of 235 decided analyses: 180 favor sglt2 inhibitors, 47 find no difference, 8 favor the comparator.
Papers
- Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.Trial report · 2012
- Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.Trial report · 2018
- Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.Trial report · 2015
- Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial.Trial report · 2025
- Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial.Trial report · 2017
- Empagliflozin as add-on to metformin in people with Type 2 diabetes.Trial report · 2015
Trials
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese SubjectsNCT02243202 · 10 posted results
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese SubjectsNCT00650806 · 24 posted results
- A 12-Week, Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety, Tolerability and Efficacy Of Once Daily PF-04971729 And Sitagliptin On Glycemic Control And Body Weight In Adult Patients With Type 2 Diabetes Mellitus Inadequately Controlled On MetforminNCT01059825 · 22 posted results
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin AloneNCT00528879 · 12 posted results
- Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With MetforminNCT02564926 · 9 posted results
- A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-Controlled,Phase III Study With a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin AloneNCT00855166 · 7 posted results
- A 24-Week,Int.,Rand.,Double-blind,Parallel-group,Multi-centre, Plac.-Controlled Phase III Study With a 24-Wk Ext.Per.to Eval.the Efficacy and Safety of Dapagliflozin in Comb.With Glimepiride (a Sulphonylurea) in Subjects With Type2 Diab.Who Have Inadeq. Glycaemic Control on Glimepiride Therapy AloneNCT00680745 · 6 posted results
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy AloneNCT00683878 · 6 posted results